The abstract is read at the publisher; the summary is JClub's.
In adults with difficult-to-treat ICD-10 depression and hs-CRP ≥0.3 mg/dL, tocilizumab showed no significant day-14 improvement in somatic symptoms (adjusted difference -0.12; 95% CI -2.51 to 2.28).
- Why it matters: Randomized evidence for whether systemic IL-6 inhibition can treat depression is limited, despite IL-6 being a mechanistic candidate linked to depressive biology.
- What they did: In a 4-week, double-blind, parallel-arm trial, 29 participants received a single intravenous infusion of tocilizumab (8 mg/kg, max 800 mg) or placebo, with outcomes measured at baseline and days 7, 14, and 28.
- The result: Across time, tocilizumab was linked to greater improvement in somatic symptoms, total severity, fatigue, psychological symptoms, state anxiety, and quality of life, with remission at day 28 (53.9% vs 31.3%; NNT=5) and response (46.2% vs 18.8%; NNT=4) favoring tocilizumab.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.